Female puberty: Clinical implications for the use of prolactin-modulating psychotropics

Child and Adolescent Psychiatric Clinics of North America

Volumn 15, Issue 1, 2006, Pages 207-220

  Becker, Amy L ^a   Epperson, C Neill ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CITALOPRAM; CLOZAPINE; FLUOXETINE; FLUVOXAMINE; GONADORELIN; GROWTH HORMONE; MIRTAZAPINE; NEFAZODONE; OLANZAPINE; PAROXETINE; PROLACTIN; QUETIAPINE; RISPERIDONE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SOMATOMEDIN; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; ZIPRASIDONE;

AMENORRHEA; BINDING AFFINITY; BONE DEVELOPMENT; BONE MASS; BONE STRENGTH; CHILD PSYCHIATRY; CLINICAL FEATURE; CLINICAL TRIAL; DEPRESSION; DEVELOPMENTAL STAGE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; FEMALE INFERTILITY; GALACTORRHEA; GILLES DE LA TOURETTE SYNDROME; HUMAN; HYPERPROLACTINEMIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MENARCHE; MENSTRUAL CYCLE; MENSTRUAL IRREGULARITY; MENTAL DISEASE; OBSESSIVE COMPULSIVE DISORDER; OSTEOPENIA; OSTEOPOROSIS; PHYSICAL DEVELOPMENT; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE; PROLACTINOMA; PROTEIN FUNCTION; PROTEIN STRUCTURE; PUBERTY; REGULATORY MECHANISM; REVIEW; SEX DIFFERENCE; TREATMENT OUTCOME;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CHILD; FEMALE; GONADAL DISORDERS; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MENTAL DISORDERS; PITUITARY-ADRENAL SYSTEM; PROLACTIN; PUBERTY;

EID: 28444458443     PISSN: 10564993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chc.2005.08.006     Document Type: Review

References (93)

1. G. Masi, S. Millepiedi, and M. Mucci Generalized anxiety disorder in referred children and adolescents J Am Acad Child Adolesc Psychiatry 43 6 2004 752 760
2. R.S. Diler, B. Birmaher, and D. Brent Phenomenology of panic disorder in youth Depress Anxiety 20 2004 39 43
3. A. Angold, and C. Worthman Puberty onset of gender differences in rates of depression: a developmental, epidemiologic and neuroendocrine perspective J Affect Disord 29 1993 145 158
4. L. Born, A. Shea, and M. Steiner The roots of depression in adolescent girls: is menarche the key Curr Psychiatry Rep 4 6 2002 449 460
5. H. Ebeling, P. Tapanainen, and A. Joutsenoja A practice guideline for treatment of eating disorders in children and adolescents Ann Med 35 2003 488 501
6. S. Gowers, and R. Bryant-Waugh Management of child and adolescent eating disorders: the current evidence base and future directions J Child Psychol Psychiatry 45 1 2004 63 83
7. L.A. Kotler, and B.T. Walsh Eating disorders in children and adolescents: pharmacological therapies Eur Child Adolesc Psychiatry 9 Suppl 1 2000 I108 I116
8. Unapproved uses of approved drugs: the physician, the package insert and the Food and Drug Administration: subject review. American Academy of Pediatrics Committee on Drugs Pediatrics 98 1 1996 143 145
9. P. Jensen, V. Bhatara, and B. Vitiello Psychoactive medication prescribing practices for US children: gaps between research and clinical practice J Am Acad Child Adolesc Psychiatry 38 5 1999 557 565
10. A. Martin, T. Van Hoof, and D. Stubbe Multiple psychotropic pharmacotherapy among child and adolescent enrollees in Connecticut Medicaid managed care Psychiatr Serv 54 1 2003 72 77
11. J. Kaye, B. Bradbury, and H. Jick Changes in antipsychotic drug prescribing by general practitioners in the United Kingdom from 1991 to 2000: a population-based observational study Br J Clin Pharmacol 56 2003 569 575
12. L. Curtis, L. Masselink, and T. Ostbye Prevalence of atypical antipsychotic drug use among commercially insured youths in the United States Arch Pediatr Adolesc Med 159 2005 362 366
13. R. Legro, H. Mo Lin, and L. Demers Rapid maturation of the reproductive axis during perimenarche independent of body composition J Clin Endocrinol Metab 85 2000 1021 1025
14. A. Demir, L. Dunkel, and U. Stenman Age-related course of urinary gonadotropins in children J Clin Endocrinol Metab 80 1995 1457 1460
15. R. Penny, I. Goldstein, and D. Frasiet Gonadotropin excretion and body composition Pediatrics 61 2 1978 294 300
16. S. Garnett, W. Hogler, and B. Blades Relation between hormones and body composition, including bone, in prepubertal children Am J Clin Nutr 80 2004 966 972
17. L. Alonso, and R. Rosenfield Oestrogens and puberty Best Pract Res Clin Endocrinol Metab 16 1 2002 13 30
18. W.A. Marshall, and J.M. Tanner Variations in the pattern of pubertal changes in girls Arch Dis Child 44 1969 291 303
19. J.R. Ducharme, and M.G. Forest Normal pubertal development J. Bertrand R. Rappaport P. Sizonenko Pediatric endocrinology: physiology, pathophysiology and clinical aspects 2nd edition 1993 Williams and Wilkins Baltimore (MD) 372 377
20. I.D. Schwartz, and B.B. Bercu Normal growth and development W. Hung Clinical pediatric endocrinology 1992 Mosby Year Book St. Louis (MO) 30 33
21. D. Apter, and E. Hermanson Update on female pubertal development Curr Opin Obstet Gyn 14 5 2002 475 481
22. R. Legro, H. Mo Lin, and L. Demers Rapid maturation of the reproductive axis during perimenarche independent of body composition J Clin Endocrinol Metab 85 2000 1021 1025
23. A.D. Rogol, J.N. Roemmich, and P.A. Clark Growth at puberty J Adolesc Health 31 2002 192 200
24. S. Mora, and V. Gilsanz Establishment of peak bone mass Endocrinol Metab Clin North Am 32 2003 39 63
25. P.M. Braillon Annual changes in bone mineral content and body composition during growth Horm Res 60 2003 284 290
26. J.E. Fares, M. Choncair, and M. Nabulsi Effect of gender, puberty and vitamin D status on biochemical markers of bone remodeling Bone 33 2003 242 247
27. G. Saggese, G. Baroncelli, and S. Bertelloni Puberty and bone development Best Pract Res Clin Endocrinol Metab 16 1 2002 53 64
28. M.K. Javaid, and C. Cooper Prenatal and childhood influences on osteoporosis Best Pract Res Clin Endocrinol Metab 16 2 2002 349 367
29. S.J. Holmes, and S.M. Shalet Role of growth hormone and sex steroids in achieving and maintaining normal bone mass Horm Res 45 1996 86 93
30. K.Y. Ho, W.S. Evans, and R.M. Blizzard Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations J Clin Endocrinol Metab 64 1 1987 51 58
31. C. Libanati, D.J. Baylink, and E. Lois-Wenzel Studies on the potential mediators of skeletal changes occurring during puberty in girls J Clin Endocrinol Metab 84 8 1999 2807 2814
32. S. Van Coeverden, J.C. Netelenbos, and C.M. de Ridder Bone metabolism markers and bone mass in healthy pubertal boys and girls Clin Endocrinol (Oxf) 57 2002 107 116
33. G. Saggese, S. Bertelloni, and G.I. Baroncelli Sex steroids and the acquisition of bone mass Horm Res 48 Suppl 5 1997 65 71
34. R. Marcus New perspectives on the skeletal role of estrogen [editorial] J Clin Endocrinol Metab 83 7 1998 2236 2237
35. P.A. Lee, and S.F. Witchel The influence of estrogen on growth Curr Opin Pediatr 9 1997 431 436
36. L.H. Duntas Prolactinomas in children and adolescents-consequences in adult life J Pediatr Endocrinol Metab 14 2001 1227 1232
37. A.S. McNeilly, A. Glasier, and I. Swanston Prolactin and the human ovary G. Tolis C. Stefanis T. Mountokalakis Prolactin and prolactinomas 1982 Raven Press New York 173 177
38. A. Wieck, and P.M. Haddad Antipsychotic-induced hyperprolactinemia in women: pathophysiology, severity and consequences Br J Psychiatry 182 2003 199 204
39. G. Laakmann, I. Chuang, and M. Gugath Prolactin and antidepressants G. Tolis C. Stefanis T. Mountokalakis Prolactin and prolactinomas 1982 Raven Press New York 151 161
40. O. Spigset, and T. Mjorndal The effect of fluvoxamine on serum prolactin and serum sodium concentrations: related to platelet 5-ht2a receptor status J Clin Psychopharmacol 17 1997 292 297
41. D.K. Arya Extrapyramidal symptoms with selective serotonin reuptake inhibitors Br J Psychiatry 165 1994 728 733
42. W. Malarkey Effects of hyperprolactinemia on other endocrine systems J. Olefsky R. Robbins Contemporary issues in endocrinology and metabolism, vol. 2: prolactinomas 1986 Churchill Livingstone New York 21 33
43. M. Molitch Manifestations, epidemiology, and pathogenesis of prolactinomas in women J. Olefsky R. Robbins Contemporary Issues in endocrinology and metabolism, vol. 2: prolactinomas 1986 Churchill Livingstone New York 67 89
44. H. Fideleff, H. Boquete, and A. Sequera Peripubertal prolactinomas: clinical presentation and long-term outcome with different therapeutic approaches J Pediatr Endocrinol Metab 13 2000 261 267
45. A. Colao, S. Loche, and M. Cappa Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up J Clin Endocrinol Metab 83 8 1998 2777 2780
46. A. Galli-Tsinopoulou, S. Nousia-Arvanitakis, and G. Mitsiakos Osteopenia in children and adolescents with hyperprolactinemia J Pediatr Endocrinol Metab 13 2000 439 441
47. A. Colao, C. Di Somma, and S. Loche Prolactinomas in adolescents: persistent bone loss after two years of prolactin normalization Clin Endocrinol (Oxf) 52 2000 319 327
48. C. Alfaro, M. Wudarsky, and R. Nicolson Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine J Child Adolesc Psychopharmacol 12 2 2002 83 91
49. S. Woods, A. Martin, and S. Spector Effects of development on olanzapine-associated adverse events J Am Acad Child Adolesc Psychiatry 41 12 2002 1439 1446
50. M. Wudarsky, R. Nicolson, and S. Hamburger elevated prolactin in pediatric patients on typical and atypical antipsychotics J Child Adolesc Psychopharmacol 9 4 1999 239 245
51. U. Naidoo, D.C. Goff, and A. Klibanski Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents Psychoneuroendocrinology 28 2003 97 108
52. R. Borison, L. Arvantis, and B. Miller ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia J Clin Psychopharmacol 16 1996 158 169
53. J. Shaw, J. Lewis, and S. Pascal A Study of quetiapine: efficacy and tolerability in psychotic adolescents J Child Adolesc Psychopharmacol 11 4 2001 415 424
54. J. Small, S. Hirsch, and L. Arvanitis Quetiapine in patients with schizophrenia Arch Gen Psychiatry 54 1997 549 557
55. A. Breier, A. Malhotra, and T.P. Su Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response Am J Psychiatry 156 2 1999 294 298
56. F. Sallee, R. Kurlan, and C. Goetz Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study J Am Acad Child Adolesc Psychiatry 39 3 2000 292 299
57. B. Kinon, J. Gilmore, and H. Liu Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials Psychoneuroendocrinology 28 2003 69 82
58. S. David, C. Taylor, and B. Kinon The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia Clin Ther 22 9 2000 1085 1096
59. B. Bronson, and J.P. Lindenmayer Adverse effects of high-dose olanzapine in treatment-refractory schizophrenia J Clin Psychopharmacol 20 3 2000 382 384
60. K. Stigler, M. Potenza, and C. McDougle Tolerability profile of atypical antipsychotics in children and adolescents Paediatr Drugs 3 12 2001 927 942
61. R. Findling, V. Kusumakar, and D. Daneman Prolactin levels during long-term risperidone treatment in children and adolescents J Clin Psychiatry 64 11 2003 1362 1369
62. D. Kleinberg, J. Davis, and R. De Coster Prolactin levels and adverse events in patients treated with risperidone J Clin Psychopharmacol 19 1999 57 61
63. S. Marder, R. McQuade, and E. Stock Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials Schizophr Res 61 2003 123 136
64. S. Mallikaarjun, D. Salazar, and S. Bramer Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers J Clin Pharmacol 44 2004 179 187
65. G. Abraham, R. Friedman, and C. Verghese Osteoporosis demonstrated by dual energy X-ray absorptiometry in chronic schizophrenic patients Biol Psychiatry 40 1996 430 431
66. G. Abraham, U. Halbreich, and R. Friedman Bone mineral density and prolactin associations in patients with chronic schizophrenia Schizophr Res 59 2002 17 18
67. M. Sagud, N. Pivac, and D. Muck-Seler Effects of sertraline treatment on plasma cortisol, prolactin and thyroid hormones in female depressed patients Neuropsychobiology 45 2002 139 143
68. M.J. Attenburrow, P.R. Mitter, and R. Whale Low-dose citalopram as a 5-HT neuroendocrine probe Psychopharmacology (Berl) 155 2001 323 326
69. R. Urban, and J. Veldhuis A selective serotonin reuptake inhibitor, fluoxetine hydrochloride, modulates the pulsatile release of prolactin in postmenopausal women Am J Obstet Gynecol 164 1991 147 152
70. J. Amsterdam, F. Garcia-Espana, and D. Goodman Breast enlargement during chronic antidepressant therapy J Affect Disord 46 1997 151 156
71. M. Dulchin, M. Oquendo, and K. Malone Prolactin response to dl-fenfluramine challenge before and after treatment with paroxetine Neuropsychopharmacology 25 2001 395 401
72. P.J. Cowen, and P.A. Sargent Changes in plasma prolactin during SSRI treatment: evidence for a delayed increase in 5-HT neurotransmission J Psychopharmacol 11 4 1997 345 348
73. K. Laine, M. Anttila, and E. Heinonen Lack of adverse interactions between concomitantly administered selegiline and citalopram Clin Neuropharmacol 20 5 1997 419 433
74. O. Spigset, and T. Mjorndal The effect of fluvoxamine on serum prolactin and serum sodium concentrations: relation to platelet 5-HT2A receptor status J Clin Psychopharmacol 17 4 1997 292 297
75. J. Morrison, R. Remick, and M. Leung Galactorrhea induced by paroxetine Can J Psychiatry 46 1 2001 88 89
76. J. Jeffries, K. Bezchlibnyk-Bulter, and G. Remington Amenorrhea and galactorrhea associated with fluvoxamine in a loxapine-treated patient J Clin Psychopharmacol 12 4 1992 296 297
77. M. Peterson Reversible galactorrhea and prolactin elevation related to fluoxetine use Mayo Clin Proc 76 2001 215 216
78. I. Iancu, G. Ratzoni, and A. Weitzman More fluoxetine experience J Am Acad Child Adolesc Psychiatry 31 4 1992 755 756
79. T. Lesaca Sertraline and galactorrhea J Clin Psychopharmacol 16 4 1996 333 334
80. M. Bronzo, and S. Stahl Galactorrhea induced by sertraline Am J Psychiatry 150 8 1993 1269 1270
81. E. Davenport A Case of paroxetine-induced galactorrhea Can J Psychiatry 47 9 2002 890 891
82. E. Gonzalez, L. Minguez, and R.M. Sanguino Galactorrhea after paroxetine treatment Pharmacopsychiatry 33 2000 118
83. V. O'Keane, and T. Dinan Prolactin and cortisol responses to d-fenfluramine in major depression: evidence for diminished responsivity of central serotonergic function Am J Psychiatry 148 8 1991 1009 1015
84. A. Emiliano, and J. Fudge From galactorrhea to osteopenia: rethinking serotonin-prolactin interactions Neuropsychopharmacology 29 2004 833 846
85. G. Laakmann, I. Chuang, and M. Gugath Prolactin and antidepressants G. Tolis C. Stefanis T. Mountakalakis Prolactin and prolactinomas 1982 Raven Press New York 151 161
86. N. Ryan, and D. Varma Child and adolescent mood disorders-experience with serotonin-based therapies Biol Psychiatry 44 1998 336 340
87. H. Sternbach Venlafaxine-induced galactorrhea J Clin Psychopharmacol 23 1 2003 109 110
88. C.U. Pae, J.J. Kim, and C.U. Lee Very low dose quetiapine-induced galactorrhea in combination with venlafaxine Hum Psychopharmacol Clin Exp 19 2004 433 434
89. G. Laakmann, C. Schule, and T. Baghai Mirtazapine: an inhibitor of cortisol secretion that does not influence growth hormone and prolactin secretion J Clin Psychopharmacol 20 1 2000 101 102
90. C. Schule, T. Baghai, and J. Goy The influence of mirtazapine on anterior pituitary hormone secretion in health male subjects Psychopharmacology (Berl) 163 2002 95 101
91. C. Schule, T. Baghai, and M. Bidlingmaier Endocrinological effects of mirtazapine in healthy volunteers Prog Neuropsychopharmacol Biol Psychiatry 26 2002 1253 1261
92. T. Csermely, L. Halvax, and E. Schmidt Occurrence of osteopenia among adolescent girls with oligo/amenorrhea Gynecol Endocrinol 16 2002 99 105
93. R. Rosenfield Diagnosis and management of delayed puberty J Clin Endocrinol Metab 70 3 1990 559 562